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Abstract
Ad5 is a common cause of respiratory disease and an occasional cause of gastroenteritis and conjunctivitis, and
seroconversion before adolescence is common in humans. To gain some insight into how Ad5 infection affects the immune
system of rhesus macaques (RM) 18 RM were infected with a host-range mutant Ad5 (Ad5hr) by 3 mucosal inoculations.
There was a delay of 2 to 6 weeks after the first inoculation before plasmacytoid dendritic cell (pDC) frequency and function
increased in peripheral blood. Primary Ad5hr infection suppressed IFN-c mRNA expression, but the second Ad5hr exposure
induced a rapid increase in IFN-gamma mRNA in peripheral blood mononuclear cells (PBMC). Primary Ad5hr infection
suppressed CCL20, TNF and IL-1 mRNA expression in PBMC, and subsequent virus exposures further dampened expression
of these pro-inflammatory cytokines. Primary, but not secondary, Ad5hr inoculation increased the frequency of CXCR3+
CD4+ T cells in blood, while secondary, but not primary, Ad5hr infection transiently increased the frequencies of Ki67+,
HLADR+ and CD95+/CCR5+ CD4+ T cells in blood. Ad5hr infection induced polyfunctional CD4 and CD8+ T cells specific for
the Ad5 hexon protein in all of the animals. Thus, infection with Ad5hr induced a complex pattern of innate and adaptive
immunity in RM that included transient systemic CD4+ T cell activation and suppressed innate immunity on re-exposure to
the virus. The complex effects of adenovirus infection on the immune system may help to explain the unexpected results of
testing Ad5 vector expressing HIV antigens in Ad5 seropositive people.
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Introduction
Since the initial description in the 1950s, adenoviruses have
been known as a cause of common childhood respiratory illnesses
[1–4]. In immunocompetent patients, most of these infections are
asymptomatic, mild, or self-limited. The prevalence of Ad5 in
North American and other populations has been assessed
serologically; almost all subjects tested have Ad5-specific binding
antibodies, of which 30–60% also have neutralizing antibody
responses [5–7]. Adenoviruses infect a broad range of animals in a
relatively species-specific manner and adenoviruses can be
persistently shed in respiratory secretions and stool [8–11].
Adenoviruses isolated from macaque monkey species (rhesus,
cynomologus) are in a different phylogenetic group from the
human adenoviruses and do not segregate with human Ad5 or
other Group C adenoviruses [11].
The biology of wild type adenoviruses is considerably different
from adenoviral vectors designed for gene therapy or as vaccine
vectors. Adenoviral vectors carry gene deletions to create space for
transgenes and/or to attenuate replication, and they are known to
induce strong inflammatory responses following administration in
humans and animal models [12,13]. In contrast, infection with
wild type Ads suppress host inflammation [14–17], a property that
may help the viruses establish persistent infection. Adenovirus
infections and adenoviral vectors induce neutralizing antibodies
and T cell immunity in nonhuman primates (NHP) and humans
[10,18–25]. Pre-existing immunity to simian Ads does not affect
Ad vector testing in NHP as the immune responses to simian Ads
do not cross-reactive with Ad5 [10]. However, very little is known
about modulation of innate immunity or immune activation
following adenovirus infection in humans or NHP.
Understanding the immune effects of wild type adenovirus
infection is of interest because of the prevalence of adenoviruses in
humans and the continued development of adenoviruses as gene
therapy and vaccine vectors for use in humans [26]. There have
been several reports that the immunity to adenoviruses acquired
through infection alters the immune response to vaccines in many
people [27–30]. In the present study, we characterized innate and
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adaptive immune responses of RM after mucosal infection with a
human host range Ad5 mutant (Ad5hr) adapted to replicate in
nonhuman primates [31]. We found that Ad5hr infection, after
repeated mucosal inoculation, had transient effects on blood
plasmacytoid dendritic cell (pDC) frequency and function and
altered the mRNA levels of antiviral and pro-inflammatory
cytokines in PBMC. Further, Ad5hr infection affected the
frequency of Ki67+CD4+, HLADR+ CD4+ and CCR5+ CD4+
T cells and putative CD4+ Treg cells in blood. Finally, Ad5hr
infection induced Ad5 hexon-specific T cell responses in blood.
Thus, Ad5hr infection of RM affects the host immune system in a
dramatic manner that could affect the immune responses to
subsequent vaccination with adenoviral vectors.
Results
Ad5hr shedding and neutralizing antibody responses in
RM
As previously reported [32], 18 male RM were inoculated with
Ad5hr orally and intranasally at week 0, then intratracheally at
weeks 8 and 12. Ad5 DNA was shed in the nasal secretions of all
animals for several days after the first inoculation, and in several
animals after the 2nd and 3rd inoculations. By 18 weeks after the
first Ad5 hr inoculation, Ad5 neutralizing antibody titers .200
had developed in all but 1 animal [32].
Delayed increase in number and function of pDC in
blood after Ad5hr infection
To assess the effect of Ad5hr infection on pDC (CD32, CD142,
CD162, CD192, CD202, CD562, HLA-DR++, and CD123+)
frequency and function, the absolute number of pDC in blood and
the ability of blood pDC to produce IFN-alpha in response to in-
vitro stimulation with herpes simplex virus were determined
[33,34]. There was a significant increase in the mean number of
pDC in blood of the Ad5hr infected RM relative to pre-infection
levels at 2 weeks (p,0.01, Fig 1A) and 18 weeks (p,0.05, Fig 1A)
after the first Ad5hr inoculation. Relative to pre-infection levels,
there was a significant increase in the mean number of IFN-alpha-
producing pDCs in the blood of the Ad5hr infected RM 6 weeks
(p,0.05, Fig 1B) and 18 weeks after the first Ad5hr inoculation
(p,0.01, Fig 1B).
Increased frequencies of putative regulatory T cells
(Tregs) in blood after Ad5hr infection
To assess the effect of Ad5hr infection on CD4+ regulatory T
cells, we evaluated the frequency of CD4+ Treg (Foxp3+/CD25hi)
and a CD4+ Treg subset expressing CTLA4 (Foxp3+/CTLA4+/
CD25hi) that is thought to be particularly immunosuppressive, as
CTLA4 is required for suppression by Tregs [35]. There was a
significant increase in frequency of CD4+ Treg at 4, 12 and 18
weeks (p,0.001, Fig 2A) and CTLA4+/CD4+ Treg frequency at
1, 12 and 18 weeks (p,0.05, Fig 2B) after the first Ad5hr
inoculation. After each increase, the frequency of both Treg
subsets decreased to the pre-infection levels (Fig. 2).
Increased frequencies of CCR5+ CD4+ T cells, HLADR+
CD4+ T cells and Ki67+ CD4+T cells in blood after the
second Ad5hr re-infection
The frequency of CCR5+ CD4+ T memory cells in blood
increased at week 1 after primary Ad5hr infection (p,0.01,
Fig 3A), then returned to pre-infection levels. However, after the
second and third Ad5hr inoculations at weeks 8 and 12, the
frequency of circulating CCR5+ CD4+ T cells at weeks 9, 10, 12
and 13 (p,0.001–0.05, Figure 3A) were elevated. After the second
and third Ad5hr inoculations, there were also significant increases
in the frequency of HLADR+CD4+ T cells at week 9 (p,0.001,
Fig 3B) and week 16 (p,0.05, Fig 3B). We also found that the
frequency of activated/proliferating Ki67+ CD4+ T cells was
increased at week 9 (p,0.001, Fig 3C) and week 14 (p,0.01,
Fig3C), after the second and third Ad5hr inoculations.
Reduced expression of proinflammatory cytokine and
chemokine mRNAs in PBMC after Ad5hr infection
The mRNA levels of IFN-gamma, IFN-alpha, IL-1, CCL20 and
TNF in PBMC were variably affected by the primary Ad5hr
infection (Fig 4 A–E), but IL-1, CCL20 and TNF were
significantly decreased after subsequent Ad5 exposures (Fig 4).
In contrast, there were small but significant increases in IFN-
gamma mRNA expression in PBMC (p,0.05, Fig 4 A) after the
second Ad5hr exposure (weeks 9 & 12), which decreased following
the 3rd exposure.
Ad5hr infection induced polyfunctional hexon-specific T
cell responses in blood
We evaluated the T cell responses in PBMCs of the Ad5hr -
inoculated RM to 3 pools of overlapping peptides representing the
Figure 1. Effect of Ad5hr infection on the number and function
of circulating pDC. A) number of pDC per ml of blood. B) number of
IFN-a secreting pDCs per ml of blood. Arrows on the X axis indicate the
time of Ad5hr inoculation. The mean values for all animals are indicated
by blue bars. P values #0.05 from the ANOVA and Dunnetts’s post-hoc
tests are shown.
doi:10.1371/journal.pone.0106004.g001
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aa sequence of the Ad5 hexon protein. Moderate Ad5 hexon-
specific CD8+ and CD4+ T cell responses (.2 fold increase vs
pre-infection) were detected in about half of the RM at week 2
(Table 1). The hexon-specific T cells induced after primary Ad5hr
infection produced 1–3 of the cytokines measured (Fig 5).
Subsequent Ad5hr exposures (week 8 and 12) led to detectable
hexon-specific CD4+ T cell responses in about 77% of RM
(Table 1). By week 14, after 3 mucosal Ad5hr exposures, the
hexon-specific CD4+ and CD8+T cell responses were more
polyfunctional than the hexon-specific T cells detected at week 2
(Fig 5). Of note, the breadth of the hexon-specific T cell responses,
as measured by the number of peptide pools eliciting positive
responses, was maximum at week 10 after the second Ad5hr
inoculation and most restricted at week 14 after 3 Ad5hr
inoculations (Table 1).
Discussion
We previously showed that after RM are inoculated with
Ad5hr, virus is consistently shed in feces and respiratory secretions
after the first Ad5hr inoculation but shedding is intermittent after
the second and third inoculations [32]. The pattern of virus
shedding in Ad5hr-infected RM mirrors Ad5hr shedding in
humans. Adenovirus shedding from the lower GI tract is common
in children during symptomatic and asymptomatic infections and
it also occurs in healthy adults [36–39]. A recent study found
adenoviruses in 7.1% of approximately12,000 respiratory samples
from pediatric populations with respiratory symptoms, and there
was a high rate of adenovirus co-infection (21.7%) with multiple
serotypes in many positive samples [40]. Although Ad5 infected
RM and humans develop potent neutralizing antibody responses
and Ad5-specific T cells responses [10,18–25,32], the pattern of
virus shedding suggests that this immunity does not prevent re-
infection. Further anti-Ad5 immunity is often incapable of
completely clearing Ad5 infections as the virus can persist in
mucosal surfaces of humans [8] and RM [9] for months.
The tropism of Ad5hr in RM and Ad5 in humans is similar and
could explain how Ad5 infection affects innate immunity. The
coxsakie virus adenovirus receptor (CAR) which binds to the knob
domain of the fiber protein, is described as the primary receptor
for human adenoviruses [41,42]. However, a number of cells that
do not express CAR support adenovirus replication. In fact CAR
has been shown to play a minor role in Ad5 infection of many cell
types including epithelial cells. Further, human monocytes and
dendritic cells (DCs) are susceptible to Ad5 infection despite their
lack of CAR expression [43,44]. Although Langerhans cells and
dermal DCs from skin express CAR, blocking CAR does not block
Ad5 infection, indicating that other receptor pathways mediate
viral entry into these cells [45]. Ad5hr in rhesus macaques and
Ad5 in humans target lung and gut macrophages and dendritic
cells [9]. Thus biology of Ad5hr infection of RM and Ad5
infection of humans are very similar. The affinity of Ad5 for long-
lived antigen presenting cells, macrophages and DC in mucosal
sites may partially explain the ability of these infections to suppress
innate immunity and induce systemic CD4+ T cell activation.
Figure 2. Effect of Ad5hr infection on CD4+ Treg frequency. A)
The frequency of FOXP3+/CD4+ T cells that express a high level of CD25
in blood. B) The frequency of CTLA4+/CD25hi/ CD4+ T cells in blood. C)
The frequency of FOXP3+/CTLA4+/CD25hi/ CD4+ T cells in blood. Arrows
on the X axis indicate the time of Ad5hr inoculation. The mean values
for all animals are indicated by blue bars. P values £ 0.05 from the
ANOVA and Dunnetts’s post-hoc tests are shown.
doi:10.1371/journal.pone.0106004.g002
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Here we find report that Ad5hr infection affects the RM
immune system in a variety of ways, with repeated exposures
having complex and additive effects. The host innate immune
system was suppressed by Ad5hr infection as evidenced by changes
in the number and function of pDC in blood and decreased
expression of pro-inflammatory and immunoregulatory cytokines
and chemokine mRNAs in PBMC. Ad5hr infection also altered
the adaptive immune system of the host, transiently increasing the
frequency of activated T cells and CD4+ T cells expressing Treg
markers in blood.
There was a transient increase in pDC frequency and function 2
weeks after the initial Ad5hr exposure (Fig 1A& 1B); however,
there was no change from pre-inoculation levels in the pDC
frequency or function at week 1 after Ad5hr inoculation while viral
replication was at its peak. Thus primary Ad5hr exposure did not
appear to induce strong antiviral pDC immune responses in blood.
To further understand the Ad5hr induced effects on the immune
system, we characterized the antiviral/proinflammatory cytokine
and chemokine mRNA expression levels in PBMCs of Ad5hr-
infected RM. There was little change in cytokine or chemokine
mRNA levels in PBMC at week 1 after the first Ad5hr exposure.
Thus, at the gene expression level primary Ad5hr exposure did not
induce, and may have suppressed, strong antiviral and pro-
inflammatory immune responses in blood 7 days after oral
inoculation. In contrast, 7- 14 days after subsequent Ad5hr
exposures there was a very transient increase in IFN-gamma
mRNA in PBMCs. Although IFN-gamma is a key molecule of
antiviral defenses [46,47], it also increases the levels of immune
activation and inflammation in response to infection [48,49]. Thus
the expression of molecules associated with innate antiviral
response was suppressed in PBMC by primary Ad5 infection
and, with the exception of IFN-gamma, secondary Ad5 infections/
exposures reinforced and broadened this effect.
Human pDC infected in vitro with Ad5 or other Group C
adenoviral strains do not produce inflammatory cytokines, in
contrast to Group B and E strains [10], and in marked contrast to
E1-deleted Ad5 vectors [50]. It seems likely that the inhibition of
pDC responses and antiviral/proinflammatory cytokine and
chemokine responses that we found in PBMCs of RM infected
with Ad5hr is due to the expression of immunomodulatory viral
gene products in the initial stages of infection when viral
replication is unrestricted by host immunity. The viral proteins,
E1 & E3, are the most likely mediators of this immunomodulation.
These viral proteins suppress NFkB activation and the subsequent
inflammatory response following Ad5 infection [14–16]. However,
after the second and third Ad5hr inoculations, Ad5hr-specific
immune responses may have blunted virus replication, with
reduced expression of E1 & E3 and less suppression of interferon
but not other innate immune responses.
After primary Ad5hr infection there was an increased frequency
of activated CD4+ T cells in blood, although the levels of these
cells quickly returned to baseline. However, subsequent Ad5hr
exposures induced recurrent CD4+T cell activation, including
expression of Ki67, a marker associated with T cell proliferation.
Thus, as with IFN-gamma expression in PBMC, repeated Ad5hr
exposure was necessary to induce systemic CD4+ T cell activation,
which although not sustained, recurred upon re-exposure to Ad5.
Similar transient CD4+ T cell activation was observed in RM after
vaccination with an E1-deleted, replication defective Ad 5 vector
[51]. As people are likely to be repeatedly exposed to Ad5,
Figure 3. Effect of Ad5hr infection on the frequency of
circulating CD4+T cells expressing activation markers. A) The
percentage of CD95+/CD3+/CD4+ cells expressing CCR5. B) The
percentage of CD3+/CD4+ cells expressing a high level of HLA-DR. C)
The percentage of CD3+/CD4+ cells expressing Ki67. Arrows on the X
axis indicate the time of Ad5hr inoculation. The mean values for all
animals are indicated by blue bars. P values#0.05 from the ANOVA and
Dunnetts’s post-hoc tests are shown.
doi:10.1371/journal.pone.0106004.g003
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frequent periods of transient T cell activation probably occur with
some frequency in Ad5 seropositive individuals.
A recent report showed that Ad5 immune complexes interact
with Fc receptors on DC to enter the endosomal compartment
where Ad5 genomic DNA interacts with TLR9 [52]. This TLR9
ligation activates DCs and results in production of proinflamma-
tory cytokines. If this type of interaction occurs in vivo, it could
activate Ad5-specifc and bystander T cells after secondary Ad5hr
exposures. Because as we previously reported Ad5hr infection of
RM induces Ad5-specific antibodies [32], this phenomenon could
explain the enhanced virus transmission after Ad5 seropositive
individuals were immunized with rAd5 Merck Step vaccine.
The frequency of Tregs in blood after the primary Ad5hr
infection increased (Fig 2). This response to Ad5hr infection by RM
is not unique, as upregulation of Tregs early after pathogen
infection [53–55] with concomitant modulation of pathogen-
specific immunity has been recently reported [54,56]. Furthermore,
CTLA4 expression on Tregs is associated with Treg-mediated
immune suppression 36 [57]. It has been shown that Tregs promote
pathogen persistence in leishmania and TB infection [53,55].
After Ad5hr infection RM develop weak and variable hexon-
specific CD4+ and CD8+ T cell responses in the blood. These
hexon-specific T cells predominantly secreted 1–3 cytokines in
various combinations (Table 1, Fig 5). Secondary Ad5hr expo-
sures expanded hexon-specific CD4+ T cell responses (Table 1)
with increases in polyfunctional T cells; especially IFN-gamma +/
TNF+/IL-2+ CD4+ T cells (Fig 5). Similarly Ad5-specific CD4+
and CD8+ T cells are found in humans and CD4+ T cell
responses are focused on the hexon protein [21,23].
Although, preexisting Ad5 specific immunity does not prevent
infection, it does affect the immunogenicity of Ad5-based vaccines
in RM and humans [27–30,32]. Adenovirus Immunity at the time
of immunization with the Step vaccine modified T helper cell
cytokine responses to the vaccine [28], reduces innate immune
responses [30] and is associated with relatively poor HIV-specific
T cell responses in both human and RM Step vaccine recipients
[27,32]. Ad5-immunity present in the host prior to Ad5 vaccine
immunization result in weaker HIV or SIV-specific T cell
responses in that less vaccinees respond, and the magnitude,
antigenic breadth and cytokine functions of the HIV/SIV-specific
T cells were reduced compared to their Ad5 seronegative
counterparts [27,32]. How the pre-existing Ad5 immunity affects
the responses to vaccines has not been rigorously determined. The
lower immune responses to HIV antigens in Ad5 seropositive
people immunized with an Ad5 vector is assumed to be due to the
killing of these APC as they express HIV and Ad5 antigens by pre-
existing Ad5-specific memory cytotoxic T cells. In addition,
preexisting Ad5-specific antibodies could form immune complexes
with Ad5 vaccine virus that activate and expand Ad5-specific
memory T cell responses. These Ad5-specific T cells, in turn,
could limit HIV-specific immune responses to the vaccine by
killing the DCs co-expressing Ad5 and HIV antigens [52].
The results reported here further demonstrate that Ad5hr
infection alters the host immune system in complex ways that
could affect the host response to subsequent vaccination,
particularly if an immunization was given just before, or after, a
secondary Ad5 infection/exposure. The Step Trial HIV vaccine
resulted in enhanced infection in some Ad5-seropositive, uncir-
cumcised vaccinees [58]. A vaccine study in macaques that
modeled the Step Trial recapitulated the lack of protection and a
greater risk of infection in immunized macaques with pre-existing
Ad5 seropositivity [32]. In both the Step trial and the monkey
study, enhanced susceptibility to infection was only seen in
individuals with a prior or ongoing Ad5 infection. However, there
is no evidence from these studies, or from HVTN 505 (the most
recent efficacy trial of a HIV vaccine using a replication defective
Ad5 vector in Ad5 seronegative men), that a replication defective
Ad5 vector vaccine can enhance HIV transmission in individuals
that are not, or have not been, infected with Ad5. Further, Ad5
infection alone is not associated with increased risk of HIV
infection AIDS [59]. Thus the results reported here, taken
together with the results of the clinical trials, raise the possibility
that Ad5 infection alters the responses to immunizations in
general. Additional experiments are needed to determine the
relative contributions of the Ad5 vector and Ad5 infections to the
Figure 4. Effect of Ad5hr infection on proinflammatory cytokine and chemokine gene expression in PBMC. A) The fold-change of IFN-
gammamRNA in PBMCs; B) IFN-a; C) IL-1; D) TNF and E) CCL20. The fold-change in target gene mRNA levels in study animals post-Ad5hr infection
relative to the same target gene mRNA level before Ad5hr infection was calculated as described in Materials and Methods. Arrows on the X axis
indicate the time of Ad5hr inoculation. The mean values for all animals are indicated by blue bars P values #0.05 from the ANOVA and Dunnetts’s
post-hoc tests are shown.
doi:10.1371/journal.pone.0106004.g004
Table 1. Adenovirus hexon-specific T cell responses in PBMCs after Ad5hr infection.
Week 2 Week 10 Week 14
Peptides/T cell # events* % positive{ # events % positive # events % positive
Pool 1/CD4 101636 44 175641` 78 68619 56
Pool 2/CD4 92630 44 264648` 72 65616 56
Pool 3/CD4 106675` 50 164629` 72 110625` 78
Pool 1/CD8 186676` 33 85614 67 73618 28
Pool 2/CD8 73634 44 99614 61 43612 56
Pool 3/CD8 122652` 28 113635` 61 97628` 56
* Flow cytometric events (mean 6SE) normalized to 105 CD3+ T cells.
{ Percentage of responders /18 animals tested.
` Responses that were $ two-fold compared to pre-infection levels were considered strongly positive.
doi:10.1371/journal.pone.0106004.t001
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unexpected outcomes of the Step trial and nonhuman primate
studies.
Materials and Methods
Ethics Statement
As previously reported [32], the captive-bred 4–9 year old male
rhesus macaques (Macaca mulatta) used in this study were from
the California National Primate Research Center and they were
housed in accordance with the recommendations of the Associ-
ation for Assessment and Accreditation of Laboratory Animal
Care International Standards and with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The Institutional Animal Use and
Care Committee of the University of California, Davis, approved
these experiments (Protocol # 15835). When immobilization was
necessary, the animals were injected intramuscularly with 10 mg/
kg of ketamine HCl (Parke-Davis, Morris Plains N.J.). All efforts
were made to minimize suffering. Details of animal welfare and
steps taken to ameliorate suffering were in accordance with the
recommendations of the Weatherall report, ‘‘The use of non-
human primates in research’’. Animals were housed in an air-
conditioned facility with an ambient temperature of 21–25uC, a
relative humidity of 40%–60% and a 12 h light/dark cycle.
Animals were individually housed in suspended stainless steel wire-
bottomed cages and provided with a commercial primate diet.
Fresh fruit was provided once daily and water was freely available
at all times. A variety of environmental enrichment strategies were
employed including housing of animals in pairs, providing toys to
manipulate and playing entertainment videos in the animal rooms.
In addition, the animals were observed twice daily and any signs of
disease or discomfort were reported to the veterinary staff for
evaluation. For sample collection, animals were anesthetized with
10 mg/kg ketamine HCl (Park-Davis, Morris Plains, NJ, USA) or
0.7 mg/kg tiletamine HCl and zolazepan (Telazol, Fort Dodge
Animal Health, Fort Dodge, IA) injected intramuscularly. The
animals were sacrificed by intravenous administration of barbitu-
rates prior to the onset of any clinical signs of disease.
Ad5hr infection
As previously reported [32], 18 RM were infected with 1.56109
infectious particles/dose/route of Ad5hr [31], by nasal & oral
routes at week 0 and by the intratracheal route at week 8 and 12.
Isolation of lymphocytes from blood
PBMCs were isolated from heparinized blood using Lympho-
cyte Separation Medium (ICN Biomedicals). PBMC samples were
frozen in 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and
90% fetal bovine serum (Gemini BioProducts), stored in liquid
nitrogen until future use in immunological assays [32].
T cell phenotyping in blood
Blood samples were surface stained with 4 color panels of
antibodies. Panel 1; anti-CD3 PerCP clone no. SP34, anti-CD4
APC clone no. M-T477, anti-CD95 FITC clone no. DX2 and
anti-CCR5 PE clone no. 3A9. Panel 2; anti-CD3 PerCP clone
no. SP34, anti-CD8 APC clone no. SK1, anti-CD38 PE clone
OKT10, anti-HLADR FITC clone no G46-6. Surface stained
samples were fixed with Q prep (Beckman Coulter). All antibodies
were purchased from Pharmingen/Becton-Dickinson, San Diego,
CA, unless specified. Data were acquired using a FACS Calibur
cytometer (Becton Dickinson), and analyzed using FlowJo software
(Treestar, Inc.) and a Macintosh G5 computer (Apple, Inc.). At
least 100,000 small lymphocyte events were collected from each
tube analyzed.
Intracellular staining for Ki-67 in blood
Blood samples were surfaced stained with the following
antibodies; anti-CD3-Pacific Blue (Clone SP3F2), anti-CD4-
Figure 5. Ad5 hexon-specific T cell responses in PBMCs after Ad5hr infection as detected by multiparameter flow cytometry. Pie
charts present the average CD4+ or CD8+T cell responses for all positive animals at weeks 2, 10 and 14 from the first Ad5hr inoculation, as described
in Materials and Methods. Pie slice colors denote the number of positive functions (expression of IL-2, IFN-c, TNF and CD107 degranulation). Pie arc
colors denote the 4 functions separately. Red numbers in the center of pie charts are the mean 6 standard deviation of hexon-specific T cells
normalized to 105 CD3+ T cells. Fractional numbers below a pie chart refer to the number of animals in a group of 18 that responded.
doi:10.1371/journal.pone.0106004.g005
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Amcyan (Clone L200), anti-CD8-Cy7APC (Clone SK1) and anti-
CXCR3-PE (clone 1C -6). Thereafter, surface stained samples
were washed and permeabilized with 0.5% saponin for intracel-
lular staining, and then stained with Ki67-FITC (Clone B56) for
20 min. Ki67- stained samples were washed with the permeabiliz-
ing buffer and fixed with 1% paraformaldehyde.
Intracellular staining for cytokine and degranulation
markers
As previously described in detail [32], for intracellular staining
of PBMCs, cryopreserved samples were thawed and rested
overnight at 37uC, in 5% CO2 atmosphere, in RPMI media
(Gibco, Invitrogen Inc.) containing 10% fetal calf serum. To
stimulate cells, 3 peptide pools spanning the hexon protein, 20mer
peptides overlapping by 10 residues (Anaspec, Inc.), were prepared
at 5 mg/ml/peptide in DMSO. The negative control contained co-
stimulatory molecules and DMSO, and the positive control was
staphylococcal enterotoxin B (0.2 mg/ml, Sigma-Aldrich). At least
100,000 events in the forward scatter/side scatter lymphocyte gate
were acquired. Further, samples that had a large discrepancy
between the number of events in the negative control and the
peptide-stimulated tubes were eliminated. The background level of
cytokine staining varied from sample to sample. Samples were
considered positive in which, after subtracting the negative
control, there were at least 5 positive events for a single functional
marker, 3 positive events for two or more functional markers, and
the sum of the different combinations of responses represented at
least 10 events. In addition, a sample was not considered positive
for a particular combination of functions if the frequency of T cells
responding with that particular combination of functions was
lower than 0.02%. The software program Simplified Presentation
of Incredibly Complex Evaluations (SPICE; a gift from M.
Roederer, Vaccine Research Center, NIAID/NIH) was used to
create the pie charts that represent the average of all positive
responses [60].
Relative quantification of cytokine/ chemokine mRNA
expression levels in PBMC
The mRNA levels were determined by real-time PCR as
described previously [61,62] for IL-1, IFN-alpha, IFN-gamma,
TNF and CCL20. The comparative threshold cycle (Ct) method
was used for quantification of mRNA levels (User Bulletin No. 2,
ABI PRISM 7700 Sequence Detection System, Applied Biosys-
tems). GAPDH was used as the reference gene and all samples
were tested in duplicate. A DCt value was generated by subtracting
the Ct value of GAPDH from the Ct value of the target mRNA.
To compare the target gene mRNA levels pre- and post- Ad5hr
infection, the mean DCt of a target gene at a pre-infection time
point in an individual animal was used as a reference value to
generate the DDCt for the same target gene in the that particular
animal at post-infection time points [63]. Thus, the DDCt value of
a target gene in study animals at post-infection time point is equal
to difference between DCt value of the target gene in the study
animal at a post-infection time point and the DCt value of the
target gene in that animal at the pre-infection time point. The fold-
change in target gene mRNA levels in study animals post-Ad5hr
infection relative to target gene mRNA levels in the study animals
pre-Ad5hr infection was calculated using one of 2 formulas based
on the DDCt:
1) Fold change of decreased mean mRNA level =21/22DDCt (If
the DDCt was positive).
2) Fold change of increased mean mRNA level = 22DDCt (If the
DDCt was negative).
pDC enumeration and assessment of IFN-alpha
production
Plasmacytoid DCs were phenotyped using a lineage marker Ab
cocktail (CD3, CD14, CD16, CD19, CD20, CD56) and anti-
CD123, as previously described [34].
Statistical analyses
Data are reported as the median and the standard error of the
mean (SEM) for each animal group using Prism 5.0 software
(GraphPad Software). Statistical analyses were performed by one-
way ANOVA with Dunnetts’s multiple comparison test if more
than two groups were compared. The flow cytometric data
analysis program, SPICE, was used to analyze T cell responses
detected by polychromatic flow cytometry. A P value of,0.05 was
considered significant.
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